Boston, MA -- (SBWIRE) -- 10/16/2013 -- The Partnering Agreements with Intermune 2005-2013 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

This report provides all the information you require to better understand Intermune and its partnering interests and activities over the past seven years.

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.

The report will be delivered in PDF format within 3 working days of receipt of order.

This report provides all the information you require to better understand Intermune and its partnering interests and activities over the past seven years.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

View Full Report Details and Table of Contents

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives.

The initial chapters of this report provide an orientation of bigpharma's dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.

Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Medivation, Inc. (MDVN) - Financial and Strategic SWOT Analysis Review
- Medivation, Inc. (MDVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013
- Xtandi (Prostate Cancer) - Forecast and Market Analysis to 2022
- Prostate Cancer - Pipeline Review, H2 2013
- Huntington's Disease Global Clinical Trials Review, H2, 2012
- Emerging Pharma Catalysts: H2 2012
- Huntington's Disease Global Clinical Trials Review, H2, 2013
- PharmaLeaders: CRO Benchmark Report - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs
- Food Service at the Service Station Channel in Europe